NewLink Genetics

E414780

NewLink Genetics is a biopharmaceutical company known for developing immuno-oncology therapies and infectious disease vaccines, including holding rights to the rVSV-ZEBOV Ebola vaccine candidate.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (1)

Label Occurrences
NewLink Genetics canonical 2

Statements (45)

Predicate Object
instanceOf biopharmaceutical company
public company
collaboratedWith Genentech
Merck & Co.
Roche
conducts clinical trials
country United States of America
surface form: United States
developed HyperAcute Lung vaccine
HyperAcute Pancreas vaccine
immuno-oncology drug candidates
indoximod
navoximod
focusesOn immuno-oncology therapies
infectious disease vaccines
small-molecule immunotherapies
vaccine-based immunotherapies
foundedBy Charles J. Link Jr. NERFINISHED
hasCEO Charles J. Link Jr. NERFINISHED
hasClinicalProgram Ebola vaccine trials
combination immunotherapy trials
hasIntellectualProperty immuno-oncology patents
vaccine technology patents
hasPlatform IDO pathway inhibition
hasTechnology HyperAcute cellular immunotherapy platform
headquartersLocation Ames, Iowa
heldRightsTo rVSV-ZEBOV
surface form: rVSV-ZEBOV Ebola vaccine candidate
holdsRightsTo Ebola vaccine technology licenses
industry biopharmaceuticals
biotechnology
listedOn NASDAQ
partneredWith Biomedical Advanced Research and Development Authority
U.S. government agencies
regulatoryInteraction European Medicines Agency
Food and Drug Administration
surface form: U.S. Food and Drug Administration
researchArea checkpoint inhibition
metabolic pathways in cancer
specializesIn cancer immunotherapy
infectious disease immunotherapy
oncology
stage clinical-stage
state Iowa
therapeuticArea melanoma
pancreatic cancer
solid tumors
tickerSymbol NLNK

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

rVSV-ZEBOV licensedTo NewLink Genetics
Ervebo hasDeveloper NewLink Genetics